Adjuvant Global Health Technology Fund, L.P. 13D and 13G filings for AN2 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-28 7:57 pm Sale | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Adjuvant Global Health Technology Fund, L.P. | 2,373,500 7.900% | -100,000 (-4.04%) | Filing |
| 2024-02-09 07:06 am Sale | 2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Adjuvant Global Health Technology Fund, L.P. | 2,473,500 8.300% | -123,880 (-4.77%) | Filing |
| 2023-02-10 4:57 pm Purchase | 2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Adjuvant Global Health Technology Fund, L.P. | 2,597,380 13.400% | 2,597,380 (New Position) | Filing |